The Department of Energy, through the Lawrence Livermore National Laboratory (LLNL), is offering a collaboration opportunity to further develop and commercialize modified cyclodextrins aimed at counteracting the effects of fentanyl and related opioids. This initiative seeks industry partners capable of advancing the technology, which has shown promise in binding to fentanyl and reducing its bioavailability, thereby providing a potential treatment for opioid overdoses. Given the escalating opioid epidemic, this technology represents a significant advancement in medical countermeasures, with applications in therapeutic settings, forensic research, and environmental remediation. Interested companies should submit a statement of interest, including relevant corporate expertise and contact information, to LLNL's Innovation and Partnerships Office by email or written correspondence.